At Prime Minister’s Questions on 26 June, I was pleased to hear the Prime Minister express sympathy for my 18-year-old constituent Jake Ogborne, who has spinal muscular atrophy. In May, the National Institute for Health and Care Excellence posted a press release saying that the drug Spinraza would be made available to SMA patients—the clear implication was that it would be made available to them all—only for Jake to have his hopes cruelly dashed when he was told that he was just outside the hitherto unmentioned eligibility criteria. This is a young man whose future is at stake. The Prime Minister said on that occasion that she would follow up the case. May I ask her if she has yet managed to do so?